(251 days)
Not Found
No
The document describes a mechanical implant for ankle replacement and does not mention any software, algorithms, or data processing that would indicate the use of AI/ML.
Yes
The device is intended to alleviate a disease or condition (severe rheumatoid, post-traumatic, or degenerative arthritis) by reducing pain, restoring alignment, and replacing movement in the ankle joint.
No
The device is a total ankle replacement system, which is a prosthetic device used to restore mobility and reduce pain in patients with damaged ankle joints. It is a treatment device, not one used for diagnosis.
No
The device description clearly states that the device consists of physical components (tibial trays, talar domes, and tibial inserts) made from materials like titanium alloy, cobalt chrome, and UHMWPE. This indicates a hardware-based medical device, not a software-only one.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is a total ankle replacement system designed to restore mobility, reduce pain, and replace joint movement in patients with damaged ankle joints. This is a surgical implant, not a diagnostic test performed on samples taken from the body.
- Device Description: The description details the components of the implant (tibial trays, talar domes, tibial inserts) and the materials they are made from. This aligns with a medical device intended for implantation, not a diagnostic kit or instrument.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting specific substances or markers, or providing information for diagnosis or monitoring of a disease or condition through in vitro testing.
Therefore, the INBONE and INFINITY Total Ankle is a medical device, specifically a surgical implant, and not an IVD.
N/A
Intended Use / Indications for Use
The INBONE and INFINITY Total Ankle is intended to give a patient limited mobility by reducing pain, restoring alignment and replacing the flexion and extension movement in the ankle joint. indicated for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis.
The INBONE and INFINITY Total Ankle is additionally indicated for patients with a failed previous ankle surgery.
CAUTION: The ankle prosthesis is intended for cement use only.
Product codes
HSN
Device Description
The Inbone® and Infinity® Total Ankle Systems consist of tibial trays, talar domes and tibial inserts. The tibial trays and talar domes have modular stem connections. The tibial trays are manufactured from titanium alloy; the talar domes are manufactured from cobalt chrome; and the tibial inserts are manufactured from Ultra High Molecular Weight Polyethylene (UHMWPE).
The Inbone® and Infinity® Total Ankle Systems are intended to give a patient limited mobility by reducing pain, restoring alignment and replacing the flexion and extension movement in the ankle joint.
The design features of the Inbone® and Infinity® Total Ankle Systems are substantially equivalent to the design features of other-devices previously cleared for market.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
ankle joint
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Non-Clinical Evidence: Testing in a MR environment has found that the subject device poses minimal risk under labeled conditions of use with regard to radio frequency heating or magnetically induced displacement.
Clinical Evidence: N/A
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3110 Ankle joint metal/polymer semi-constrained cemented prosthesis.
(a)
Identification. An ankle joint metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace an ankle joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces and has no linkage across-the-joint. This generic type of device includes prostheses that have a talar resurfacing component made of alloys, such as cobalt-chromium-molybdenum, and a tibial resurfacing component made of ultra-high molecular weight polyethylene and is limited to those prostheses intended for use with bone cement (§ 888.3027).(b)
Classification. Class II.
0
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of three human profiles facing right, stacked on top of each other. The profiles are connected and appear to be a single, continuous line. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the image.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
Wright Medical Technology, Incorporated Ms. Jeanine Redden Director, Regulatory Affairs 1023 Cherry Road Memphis, Tennessee 38117
March 5, 2015
Re: K141740
Trade/Device Name: INBONE and INFINITY Total Ankle System Regulation Number: 21 CFR 888.3110 Regulation Name: Ankle joint metal/polymer semi-constrained cemented prosthesis Regulatory Class: Class II Product Code: HSN Dated: January 17, 2015 Received: February 3, 2015
Dear Ms. Redden:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
Page 2 - Ms. Jeanine Redden
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely vours.
Mark N. Melkerson -S
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known)
Device Name INBONE and INFINITY Total Ankle System
Indications for Use (Describe)
The INBONE and INFINITY Total Ankle is intended to give a patient limited mobility by reducing pain, restoring alignment and replacing the flexion and extension movement in the ankle joint. indicated for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis.
The INBONE and INFINITY Total Ankle is additionally indicated for patients with a failed previous ankle surgery.
CAUTION: The ankle prosthesis is intended for cement use only.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
__ Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
3
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
Image /page/4/Picture/0 description: The image shows the logo for Wright focused excellence. The logo has a geometric shape on the left, followed by the word "WRIGHT" in bold, uppercase letters. Below the word "WRIGHT" is the phrase "FOCUSED EXCELLENCE" in smaller, uppercase letters.
Wright Medical Technology, Inc.
1023 Cherry Road Memphis, TN 38117
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS
In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CFR 807.92, this information serves as a Summary of Safety and Effectiveness for the use of the INBONE® and INFINITY® Total Ankle Systems.
| (a)(1). Submitted By: | Wright Medical Technology, Inc. 1023 Cherry Road Memphis, TN 38117 |
|---|---|
| Date: | March 4, 2015 |
| Contact Person: | Jeanine Redden Director, Regulatory Affairs Office (901) 867-4522 Fax (901) 867-4190 |
| (a)(2). Proprietary Name: | Inbone® Total Ankle System; Infinity® Total Ankle System |
| Common Name: | Total Ankle System |
| Classification Name and Reference: | 21 CFR 888.3110 - Class II |
| Device Product Code, Device Panel: | HSN - Orthopedic |
| (a)(3). Predicate Device: | K123059 Inbone® II Total Ankle System K123954 and K140749 Infinity® Total Ankle System |
(a)(4). Device Description
The Inbone® and Infinity® Total Ankle Systems consist of tibial trays, talar domes and tibial inserts. The tibial trays and talar domes have modular stem connections. The tibial trays are manufactured from titanium alloy; the talar domes are manufactured from cobalt chrome; and the tibial inserts are manufactured from Ultra High Molecular Weight Polyethylene (UHMWPE).
The Inbone® and Infinity® Total Ankle Systems are intended to give a patient limited mobility by reducing pain, restoring alignment and replacing the flexion and extension movement in the ankle joint.
The design features of the Inbone® and Infinity® Total Ankle Systems are substantially equivalent to the design features of other-devices previously cleared for market.
5
(a)(5). Intended Use
The Inbone® and Infinity Total Ankle Systems are intended to give a patient limited mobility by reducing pain, restoring alignment and replacing the flexion and extension movement in the ankle joint.
Indications for Use
The Inbone and Infinity Total Ankle Systems are indicated for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis.
The Inbone® and Infinity® Total Ankle Systems are additionally indicated for patients with a failed previous ankle surgery.
CAUTION: The ankle prosthesis is intended for cement use only.
The indications are similar to the legally marketed predicate device.
(a)(6). Technological Characteristics Comparison
No design modifications are being made to the subject Inbone® and Infinity® Total Ankle Systems. Modification of the Instructions For Use (IFU) were made include a statement regarding the compatibility of the device with MR environments.
(b)(1). Substantial Equivalence- Non-Clinical Evidence
Testing in a MR environment has found that the subject device poses minimal risk under labeled conditions of use with regard to radio frequency heating or magnetically induced displacement.
(b)(2). Substantial Equivalence- Clinical Evidence
N/A
(b)(3). Substantial Equivalence- Conclusions
As no design changes are being made to the subject device, the design characteristics of the subject device does not raise any new types of questions of safety or effectiveness. From the evidence submitted in this 510(k) regarding testing in a MR environment, the subject device is expected to pose minimal risk under labeled conditions of use to patients when place in an MR environment and is categorized as MR Conditional.